Schaefer, Lena F.
McAlindon, Timothy E.
Eaton, Charles B.
Roberts, Mary B.
Haugen, Ida K.
Smith, Stacy E.
Duryea, Jeffrey
Driban, Jeffrey B.
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR066378)
Article History
Received: 19 October 2017
Accepted: 12 December 2017
First Online: 22 December 2017
Compliance with ethical standards
:
: Institutional review boards at the OAI clinical sites and the coordinating center (University of California, San Francisco) approved the OAI study (University of California Internal Review Board Approval Number 10–00532, Approval Date: 2/24/2017 Expiration Date: 2/23/2018).
: All participants provided informed consent.
: Dr. Haugen reports personal fees from Abbvie outside the submitted work. Dr. McAlindon reports personal fees from Sanofi Aventis, Samumed, Regeneron, Federal Trade Commission, Seikagaku Corp, Astellas, Pfizer and Tufts Medical Center Physicians Organization outside the submitted work and fees to his institution from Sanofi, Samumed, Allergan and Abbvie outside the submitted work. He also reports a patent: #7,251,609: Online Clinical Trial Methodology outside the submitted work. All other authors declare that they have no conflicting interests.